Navigation Links
Tutogen Medical, Inc. Reports First Quarter Fiscal 2008 Financial Results
Date:2/6/2008

echnologies' annual meeting of stockholders, as filed with the S.E.C. on a Schedule 14A. Information about the directors and executive officers of Tutogen and their ownership of Tutogen common stock is set forth in Tutogen's Annual Report on Form 10-K for the fiscal year ended September 30, 2007. Additional information regarding the interests of those participants and other persons who may be deemed participants in the merger may be obtained by reading the joint proxy statement/prospectus regarding the proposed merger filed with the S.E.C. on January 23, 2008. You may obtain free copies of these documents as described in the preceding paragraph.

Tutogen Medical, Inc.

Consolidated Statement of Income (Loss)

(In Thousands, Except for Share and Per Share Data)

Three Months Ended

December 31,

2007 2006

Revenue $ 14,955 $ 11,463

Cost of revenue 6,888 4,421

Gross profit 8,067 7,042

Operating Expenses

General and administrative 4,210 2,362

Distribution and marketing 4,553 3,441

Research and development 617 527

Total Operating Expenses 9,380 6,330

Operating (loss) income (1,313) 712

Foreign exchange loss (3) (38)

Interest and other income 130 34

Interest and other expense (86) (274)


'/>"/>

SOURCE Tutogen Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Tutogen Medical, Inc. to Present at the Roth Capital Partners 2007 New York Conference
2. Tutogen Medical, Inc. and Zimmer Holdings, Inc. Announce Agreement for International Distribution of Biological Products
3. Zimmer and Tutogen Announce Agreement for International Distribution of Biological Products
4. Tutogen Medical, Inc. to Report Fourth Quarter and Fiscal Year 2007 Financial Results
5. Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results
6. Nonin Medical, Inc. Receives Frost & Sullivans 2007 Award for Product Differentiation Innovation
7. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
8. QMed, Inc. Reports July Medicare SNP Enrollments
9. Phlo Affiliate Reports Expanded Coverage to Oregon Border
10. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
11. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... TORONTO , May 21, 2015 /PRNewswire/ - SQI ... SQIDF),a life sciences company that develops and commercializes proprietary ... its financial and operational results for the second fiscal ... the quarter the Company continued to advance business with ... Andrew Morris , President and CEO of SQI. ...
(Date:5/21/2015)... 2015 uBiome, the leading startup ... with PicnicHealth, a healthcare company that collects and ... Inflammatory Bowel Disease (IBD) will receive a complementary ... research kit. Both companies were funded by Y ... For more information on this partnership and how ...
(Date:5/21/2015)...  CytRx Corporation (NASDAQ: CYTR ), a ... today announced positive updated results from its ongoing ... treatment of unresectable glioblastoma multiforme (GBM), a deadly ... is designed to investigate the preliminary efficacy and ... progressed following prior treatment with surgery, radiation and ...
(Date:5/21/2015)... (PRWEB) May 21, 2015 Tunnell ... joined the firm as senior statistician and Principal, a ... of experience in the management and analysis of complex ... and chemical industries. , “We’re delighted to have Julia ... in data analytics,” said Dr. Philippe Cini, Group Vice ...
Breaking Biology Technology:SQI Diagnostics Reports Second Quarter Financial Results 2SQI Diagnostics Reports Second Quarter Financial Results 3SQI Diagnostics Reports Second Quarter Financial Results 4SQI Diagnostics Reports Second Quarter Financial Results 5SQI Diagnostics Reports Second Quarter Financial Results 6SQI Diagnostics Reports Second Quarter Financial Results 7SQI Diagnostics Reports Second Quarter Financial Results 8uBiome Partners with PicnicHealth 2uBiome Partners with PicnicHealth 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Julia O’Neill Joins Tunnell Consulting’s Operational and Process Improvement Practice 2
... As ... ... as other commercial real estate sectors struggle, investors continue to pour hundreds of millions ... new debt and $30 million in new equity from Prudential Real Estate Investors (PREI), ...
... , SAN DIEGO, July 30 ... plans to develop a DNA-based orthobiologics product portfolio based on ... initially focus on non-union bone fractures for medically-compromised patients, and ... is a rapidly growing segment of the orthopedics market and ...
... PDI, Inc. (Nasdaq: PDII ), a leading provider of ... PDI director Gerald P. Belle has been appointed to the newly-established position ... has been a director of the Company since April 2008. He is ... "Jerry has served as an invaluable board member during his tenure with ...
Cached Biology Technology:Millions Flowing into Medical Real Estate 2Millions Flowing into Medical Real Estate 3Cardium Announces New Orthobiologics Product Initiative Extending Gene Activated Matrix Technology to Deliver Bone Growth Factors 2Cardium Announces New Orthobiologics Product Initiative Extending Gene Activated Matrix Technology to Deliver Bone Growth Factors 3Cardium Announces New Orthobiologics Product Initiative Extending Gene Activated Matrix Technology to Deliver Bone Growth Factors 4Cardium Announces New Orthobiologics Product Initiative Extending Gene Activated Matrix Technology to Deliver Bone Growth Factors 5Cardium Announces New Orthobiologics Product Initiative Extending Gene Activated Matrix Technology to Deliver Bone Growth Factors 6Cardium Announces New Orthobiologics Product Initiative Extending Gene Activated Matrix Technology to Deliver Bone Growth Factors 7Cardium Announces New Orthobiologics Product Initiative Extending Gene Activated Matrix Technology to Deliver Bone Growth Factors 8Cardium Announces New Orthobiologics Product Initiative Extending Gene Activated Matrix Technology to Deliver Bone Growth Factors 9Cardium Announces New Orthobiologics Product Initiative Extending Gene Activated Matrix Technology to Deliver Bone Growth Factors 10PDI Appoints Gerald P. Belle as Lead Independent Director 2PDI Appoints Gerald P. Belle as Lead Independent Director 3
(Date:4/13/2015)...  higi, a leading cloud-based consumer engagement platform that ... with their communities around health and wellness, announced today ... API.  ... and convenient vehicle to receive validated health information from ... The API will allow higi,s trusted partners, on a ...
(Date:4/9/2015)... 9, 2015 Synaptics Inc. (NASDAQ: SYNA ), ... that it will report financial results for the third ... after the close of market. The company will host ... 2:00 p.m. PT (5:00 p.m. ET), during which management ... on the live call, analysts and investors should dial ...
(Date:4/6/2015)... , Apr. 6, 2015 NXT-ID, Inc. ... a biometric authentication company focused on the growing ... filed provisional patent 62/143028 for MINIATURE, ... ENERGY TRANSFER  NXT-ID introduces a new ... This patent surrounds the use of miniature antenna ...
Breaking Biology News(10 mins):higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3Synaptics to Report Third Quarter Results on April 23 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4
... the need for costly insulin injections for diabetics, regenerating ... disease by engineering immune cells top a list of ... emerging from the new world of regenerative medicine, according ... Public Library of Science (PLoS) Medicine. , Conducted by ...
... is highly susceptible to mammary tumors, Cornell researchers have found ... (copying) and breast cancer. , The mouse contains a mutation ... and mice that increases the rate of flawed copies of ... a paper published in Nature Genetics online (and upcoming in ...
... novel vascular targeting agent completely prevented the development of ... in a preclinical study, providing early evidence that it ... a common destination for a number of cancers when ... of Texas M. D. Anderson Cancer Center reported in ...
Cached Biology News:Replacing insulin is top-ranked breakthrough foreseen for health in developing world 2Replacing insulin is top-ranked breakthrough foreseen for health in developing world 3Replacing insulin is top-ranked breakthrough foreseen for health in developing world 4Replacing insulin is top-ranked breakthrough foreseen for health in developing world 5Replacing insulin is top-ranked breakthrough foreseen for health in developing world 6Mutant mouse provides insights into breast cancer 2'Trojan Horse' agent halts bone metastasis in mice 2'Trojan Horse' agent halts bone metastasis in mice 3
Apoptosis Detection Systems and Reagents...
... feeding tubes for rodent oral gavage feature ... of perforation and trauma. Plus they are ... and the risk of cross-contamination. ... 20ga Length: ...
Bovine Serum Available Anticoagulants: N-02: Citrate N-04: Heparin (Na) N-06: K2EDTA N-08: Potassium Oxalate N-10: EDTA (Na) N-03: Alsevers N-05: ACD N-07: CPD N-09: K3EDTA N-11:...
DAPI: 4', 6-Diamino-2-phenylindole dihydrochloride. Antifade Solution: p-Phenylenediamine and glycerol in PBS solution. 0.4g/mL DAPI suspended in Antifade....
Biology Products: